Hikma Pharmaceuticals PLC (LON:HIK – Get Free Report) shares passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 1,865.76 ($23.44) and traded as high as GBX 1,977 ($24.83). Hikma Pharmaceuticals shares last traded at GBX 1,960 ($24.62), with a volume of 289,757 shares changing hands.
Analyst Upgrades and Downgrades
A number of analysts recently issued reports on the stock. Berenberg Bank restated a “hold” rating and issued a GBX 2,000 ($25.12) price target on shares of Hikma Pharmaceuticals in a research note on Thursday, April 25th. Barclays restated an “equal weight” rating and issued a GBX 2,000 ($25.12) target price on shares of Hikma Pharmaceuticals in a research note on Monday, April 8th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 2,068.75 ($25.99).
Check Out Our Latest Stock Analysis on Hikma Pharmaceuticals
Hikma Pharmaceuticals Trading Up 1.8 %
Hikma Pharmaceuticals Increases Dividend
The firm also recently declared a dividend, which was paid on Friday, May 3rd. Stockholders of record on Thursday, March 21st were issued a $0.47 dividend. The ex-dividend date of this dividend was Thursday, March 21st. This is a positive change from Hikma Pharmaceuticals’s previous dividend of $0.25. This represents a dividend yield of 1.86%. Hikma Pharmaceuticals’s payout ratio is 8,382.35%.
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
Featured Stories
- Five stocks we like better than Hikma Pharmaceuticals
- How Investors Can Find the Best Cheap Dividend Stocks
- MarketBeat Week in Review – 4/29 – 5/3
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Compound Interest and Why It Matters When Investing
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.